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Abstract
Despite extensive progress in determining structures within heparin and heparan sulfate (Hp/HS)
and the discovery of numerous proteinaceous binding partners for Hp/HS so far; the only detailed
characterization of a specific protein-glycosaminoglycan interaction is antithrombin III (ATIII)
binding to a Hp pentasaccharide containing a unique 3-O-sulfated glucosamine residue. Previously,
it was reported from our laboratories that a 16 amino acid synthetic peptide derived from the C-
terminus of human HIP/RPL29 (HIP peptide-1) enriched for ATIII-dependent anticoagulant activity,
presumably by specifically binding the ATIII pentasaccharide. Herein, we demonstrate that HIP
peptide-1 cannot enrich ATIII-dependent anticoagulant activity from a starting pool of porcine
intestinal mucosa Hp through a bio-specific interaction. However, a HIP peptide-1 column can be
used to enrich for anticoagulantly active Hp from a diverse pool of glycosaminoglycans known as
Hp byproducts by a mechanism of nonspecific charge interactions. Thus, HIP peptide-1 cannot
recognize Hp via bio-specific interactions but binds glycosaminoglycans by non-specific charge
interactions.
Introduction
The serine protease inhibitor, antithrombin III (ATIII), is
1000 times more active when bound to a specific pen-
tasaccharide sequence within the heparin / heparan sul-
fate (HS) chain [1]. While this sequence is found with a
low frequency in HS, approximately 30% of the heparin
molecules within a commercial preparation of porcine in-
testinal mucosa heparin (Hp), contains this pentasaccha-
ride [2–5]. The ATIII – Hp complex inhibits the
coagulation cascade by inactivating serine proteases, such
as factor Xa (FXa) and thrombin. The interaction between
ATIII and the Hp pentasaccharide (ATIII binding pen-
tasaccharide) is the paradigm of a bio-specific Hp-protein
interaction.
Specific protein-Hp/HS interactions involving the ATIII
binding pentasaccharide or related sequences have been
proposed for the fibroblast growth factor receptor (FGFR)
[6], and a synthetic peptide derived from the C-terminus
of human heparin/heparan sulfate interacting protein / ri-
bosomal protein L29 (HIP peptide-1) [7]. These interac-
tions were determined partly on the basis of column
chromatography experiments. Tritiated Hp with or with-
out unlabelled Hp is applied to a column of immobilized
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FGFR or HIP peptide-1 in low salt and a proportion of Hp
flows through with apparently no affinity, while the re-
mainder binds and is eluted with high salt. FGFR and HIP
peptide-1 bound fractions were enriched in ATIII-depend-
ent anti FXa activity, presumably by specifically binding to
the ATIII binding pentasaccharide or a motif associated
with this sequence. The proposed bio-specific affinity of
FGFR for the ATIII binding pentasaccharide or related
structures has recently been challenged [8]. We also report
here that HIP peptide-1 does not select for anticoagulantly
active molecules in Hp or heparin byproducts through
bio-specific interactions.
Previous work [7] developed five lines of evidence to indi-
cate a specific interaction between HIP peptide-1 and the
ATIII binding pentasaccharide. Firstly, a large proportion
of tritiated Hp flows through a HIP peptide-1 column at
0.15 M NaCl, suggesting that most of the molecules in a
commercial preparation of tritiated Hp do not have a spe-
cific motif needed for binding. Secondly, Hp oligosaccha-
rides generated by partial deaminative cleavage with
nitrous acid show significant binding to HIP peptide-1
only when the length is an octasaccharide or higher which
is similar to that seen for ATIII binding. Thirdly, tritiated
Hp that binds with high affinity to HIP peptide-1 also
binds to an ATIII column with high affinity. Fourthly, Hp
separated by HIP peptide-1 chromatography is enriched
in ATIII-dependent FXa inhibitory activity while low affin-
ity species show a decrease in the same activity. Lastly, HIP
peptide-1 inhibits the ability of ATIII-Hp complexes to in-
hibit FXa and thrombin activity, while a scrambled pep-
tide does not. These results led us to formulate the
hypothesis that HIP peptide-1 separates Hp into anticoag-
ulantly active or inactive species by interacting with the
ATIII binding pentasaccharide in a bio-specific manner.
The data presented in this paper show that fractionation
of unlabelled Hp and tritiated Hp by HIP peptide-1 dis-
play dramatic qualitative and quantitative differences. Tri-
tiated Hp that binds to HIP peptide-1 exhibits an increase
in ATIII-dependent anti FXa activity over starting material
while an analogous preparation of unlabelled Hp fails to
do so. The differences between HIP peptide-1 fractiona-
tion of tritiated and unlabelled Hp is partly explained by
differences in the charge profiles of these two pools as
measured by anion exchange chromatographic analyses.
The validity of using the commercially available tritiated
Hp as a model for unlabelled Hp is discussed.
A second source of anticoagulantly active glycosaminogly-
cans (GAGs), called Hp byproducts, is used to analyze the
binding specificity of HIP peptide-1. This is a byproduct
from the preparation of commercial Hp and contains sev-
eral GAG species, including those of the Hp/HS subclass,
less sulfated than Hp [9]. Fractionation of Hp byproducts
by HIP peptide-1 chromatography yields a high affinity
material that is enriched in ATIII-dependent anti FXa ac-
tivity over starting material. The relative activity of the
fractionated material is proportional to the salt concentra-
tion used for elution while unbound fractions are deplet-
ed in this same inhibitory activity. However, we
demonstrate that this fractionation is not due to a bio-spe-
cific interaction between HIP-peptide-1 and the ATIII
binding pentasaccharide but due to a non-specific, charge
based mechanism resulting in the enrichment of anticoag-
ulantly active Hp from Hp byproducts.
Results
HIP Peptide-1 chromatography of heparins
Unlabelled Hp (figure 1A) or tritiated Hp (figure 1B) was
subjected to HIP peptide-1 affinity chromatography as de-
scribed in the Materials and Methods Section. Unlabelled
Hp recovered in the 0.15 M NaCl wash corresponded to
49% of the recovered material and 51% was found in the
fractions eluted with 0.50 M NaCl. However, unlabelled
Hp was "bleeding" from the column after extensive wash-
ing (up to 10 column volumes) with 0.15 M NaCl. Con-
versely, tritiated Hp eluted cleanly from the column with
68% of the recovered radioactivity in the 0.15 M NaCl
wash fractions and 32% in the 0.5 M NaCl eluate. The 0.5
M NaCl eluted materials from chromatography of both
Hp sources were tested in an ATIII-dependent anti FXa as-
say. These FXa assays (data not shown) indicated that tri-
tiated Hp materials bound by HIP peptide-1 were
enriched in anticoagulant ability over starting material
while the same unlabelled Hp fraction was not. Repeated
experiments where different amounts of unlabelled Hp
were applied to a HIP peptide-1 column followed by anal-
yses of bound fractions failed to show an enrichment of
ATIII-dependent anti FXa ability.
Anion exchange chromatography of unlabelled and tritiat-
ed Hp
We subsequently explored the possibility that the differ-
ence in the HIP peptide-1 binding ability of unlabelled
and tritiated Hp was due to a difference in the charge den-
sity of these materials. This was tested by anion exchange
chromatography of unlabelled (figure 2A) or tritiated Hp
(figure 2B) with LiCl gradient elution. All of the unla-
belled Hp is found to bind to an anion exchange column
and elute as a single broad peak with an average (deter-
mined from three separate experiments) peak LiCl con-
centration of 1.5 M. The tritiated Hp preparation is found
to contain a significant amount (38%) of material that
does not bind to the anion exchange resin even before the
start of the LiCl gradient. The bound fraction consists of
62% of the radioactivity and elutes at a peak LiCl content
of 1.0 M.Journal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
Page 3 of 10
(page number not for citation purposes)
HIP Peptide-1 affinity chromatography of heparin 
byproducts
Heparin byproducts were subjected to HIP peptide-1 af-
finity chromatography (figure 3A). Of the material ap-
plied, 76% was recovered in flow through fractions 1–17
and 24% bound to the HIP-peptide-1 matrix and eluted
between 0.22 and 0.62 M NaCl, fractions 18–27. Frac-
tions 6, 19, 22, and 24 were further analyzed for their abil-
ity to inhibit FXa activity via ATIII in an in vitro assay
(figure 3B). Flow through fraction 6 exhibited a decrease
in FXa inhibiting activity by 0.355X when compared to
Figure 1
Fractionation of Unlabelled or Tritiated Hp by HIP 
Peptide-1 Affinity Chromatography. 1 mg of unlabelled 
Hp (A) or 40 ng of tritiated Hp (B) was added to a HIP pep-
tide-1 affinity matrix, allowed to bind for 10 min and washed 
with 10 column volumes of PBS before elution of bound 
materials with high NaCl as indicated. The X-axis corre-
sponds to fraction number, and the Y-axis corresponds to 
total µg (A) or DPM (B).
Figure 2
Anion Exchange Chromatography of Unlabelled or 
Tritiated Hp. Unlabelled Hp (A) or tritiated Hp (B) was 
added to 1 ml of DEAE anion exchange resin pre-equilibrated 
in 0.05 M Acetate pH 4.0 and allowed to bind. A LiCl gradi-
ent was directly applied to the unlabelled Hp while the triti-
ated Hp was washed extensively in buffer without LiCl 
before the start of a LiCl gradient. The X-axis corresponds 
to fraction number, the left Y-axis corresponds to total µg 
(A) or DPM (B), and the right Y-axis corresponds to LiCl 
concentration.Journal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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Figure 3
Fractionation of Heparin Byproducts via HIP peptide-1 Chromatography and Determination of ATIII-depend-
ent anti FXa Activity. (A) A subsaturating amount of Hp byproducts in PBS was applied to 3 mls of a HIP peptide-1 affinity 
matrix, pre-equilibrated with PBS. Unbound materials were washed from the column by 15 ml of PBS and bound materials 
were eluted with a 0.15 to 0.70 M NaCl gradient. 1-ml fractions were collected and the amount of material and salt content in 
each fraction was quantitated as in "Materials and Methods." The X-axis corresponds to the fraction number while the left Y-
axis denotes the total amount of GAG material in each fraction. The right Y-axis gives the NaCl concentration of each fraction. 
(B) Fractions 6, 19, 22, and 24 were tested in an ATIII-dependent anti FXa chromogenic assay as described in "Materials and 
Methods."Journal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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starting material. All bound fractions exhibited increases
in FXa inhibiting activites from 1.9X to 5.4X greater than
starting material. A direct relationship between the
amount of salt needed for elution from the HIP peptide-1
matrix and the fold increase in anti-FXa activity was
observed.
Differential salt elution was used in HIP peptide-1 chro-
matography of Hp byproducts to create three pools for
subsequent analyses. Initially, Hp byproducts were added
to HIP peptide-1 column in 0.25 M NaCl with approxi-
mately 2% bound. The 0.25 M NaCl flow through was di-
luted to 0.20 M NaCl and re-applied to the HIP peptide-1
column with 9.5% of the materials binding. This bound
material was named HIP 0.20 M pool. Finally, the 0.20 M
NaCl flow through was diluted to 0.15 M NaCl and re-ap-
plied to the column with 14% of the materials binding
(HIP 0.15 M pool) and 76% of the materials present in
the final flow through (HIP flow through). As in the gra-
dient elution of Hp byproducts, the materials bound in
the presence of higher salt have an increase in FXa activity
over starting material (data not shown). HIP 0.15 M pool,
HIP 0.20 M pool and HIP flow through were used in sub-
sequent analyses.
Analyses of fractionated Hp byproducts by ion exchange 
chromatography
Unfractionated Hp byproducts and fractions obtained by
differential salt elution from a HIP peptide-1 column were
applied to DEAE anion exchange columns and eluted with
a gradient of LiCl as described in the Materials and Methods
Section. No material was detected in fractions before the
start of LiCl gradients. Hp byproducts displayed a very
broad elution profile that is indicative of this material
containing a heterogeneous population of negatively
charged molecules (figure 4A). The HIP 0.20 M pool is en-
riched in the most negatively charged materials whereas
the HIP 0.15 M pool appears to contain slightly less neg-
atively charged materials which still elute late in the chro-
matography run compared to Hp byproducts starting
material. Materials depleted of HIP peptide-1 binding spe-
cies (HIP flow through) are completely depleted of highly
negatively charged species. An ATIII affinity matrix was
also used to fractionate Hp byproducts into an ATIII bind-
ing fraction with high affinity for the protease inhibitor
and an ATIII non-binding fraction (see Materials and Meth-
ods section). These fractions were also analyzed for their
negative charge properties by an ion exchange chromatog-
raphy (figure 4B). ATIII binding species displayed an
increased charge profile when compared to Hp byprod-
ucts. However, unlike the fraction depleted of HIP pep-
tide-1 binding material, Hp byproducts depleted of ATIII
binding sites still contain highly negatively charged spe-
cies when compared to the Hp byproducts starting mate-
rial. Hp byproducts depleted of ATIII binding sites were
also applied to a HIP peptide-1 column and subsequently
eluted with a gradient from 0.15 to 1 M NaCl. It is note-
worthy that significant material required greater than 0.25
M NaCl to be eluted (data not shown) further demonstrat-
ing that ATIII and HIP peptide-1 fractionate GAGs by dif-
ferent types of molecular interactions.
Capacity of a HIP peptide-1 column for binding different 
GAG species
The binding capacity of a HIP peptide-1 column for Hp,
CS-E, DS, CS-C and bovine kidney HS (BK-HS) was ana-
lyzed. Increasing concentrations of these GAGs were
incubated with a defined amount of HIP peptide-1 Sepha-
rose and the amount of GAG bound to the gel was deter-
mined (figure 5). The curves generated show binding of
Hp and CS-E to HIP peptide-1 Sepharose with saturation
occurring over the same range, indicative of similar bind-
ing affinities. DS showed less binding over the same range
and HS or CS-C showed no binding under the experimen-
tal conditions employed. Differences in the total amounts
of materials bound were noted in parallel binding experi-
ments with Hp as a positive control. The total amount of
CS-E and DS bound at saturation were 50% and 17%, re-
spectively, of the total amount of Hp bound at saturation.
These results are consistent with the hypothesis that the
HIP peptide-1 / GAG interaction depends solely on non-
specific charge interactions.
Discussion
Previous work [7] suggested that HIP peptide-1 could en-
rich for anticoagulantly active Hp on the basis of a bio-
specific interaction with the ATIII binding pentasaccha-
ride. The goal of the current study was to substantiate this
hypothesis. However, an overwhelming amount of data
presented here demonstrates that the underlying hypoth-
esis is invalid. Although we can enrich for anticoagulantly
active Hp by HIP peptide-1 affinity chromatography using
tritiated heparin or Hp byproducts as a starting material,
this enrichment is not due to bio-specific interactions.
Furthermore, repeated chromatography experiments with
unlabelled conventional Hp as the starting material failed
to significantly enrich for ATIII binding Hp. Lastly, Zhang
et al. [10] have recently reported that HIP peptide-1 does
not protect anticoagulantly active HS from complete
heparitinase digestion.
It is clear from the current data that our samples of unla-
belled and tritiated Hp are not biochemically similar. A
significant proportion (38%) of tritiated Hp does not
bind an anion exchange column while 100% of unla-
belled Hp does. We hypothesize that this sample of triti-
ated Hp contains 38% free label and thus has no apparent
negative charge. Since the fractionation of this particular
preparation of tritiated Hp over HIP peptide-1 is similar to
the previously published observations, we can onlyJournal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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Figure 4
Elution Profiles of Hp Byproducts or Fractionated Pools from Anion Exchange Chromatography with Gradi-
ent Elution. Hp byproducts starting material (HpBP) or materials from fractionation via HIP peptide-1 (A) or ATIII (B) were 
applied to a 1-ml bed volume of DEAE sepharose in .05 M acetate, pH 4.0. Columns were washed with 10 column volumes of 
acetate buffer before application of LiCl gradients. All material bound to DEAE column and 100% eluted with LiCl. One-ml 
fractions were collected and analyzed for GAG and LiCl content as in "Materials and Methods." Arbitrary values of 100 were set 
for the elution peaks for each of the column runs with every other point multiplied by the same factor. The resulting plots are 
of LiCl concentration (X-axis) versus arbitrary amount of GAG (Y-axis).Journal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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conclude that the initial preparation also contained signif-
icant amounts of "free label". The presence of "free label"
would explain the repeated enrichment of ATIII-depend-
ent anti FXa ability seen in tritiated Hp. Rather than en-
riching for the ATIII binding pentasaccharide by HIP
peptide-1 chromatography of tritiated Hp, this chroma-
tography enriches for Hp, leaving behind "free label". This
would result in an apparent enrichment of activity per
DPM in bound tritiated Hp materials and a depletion of
activity per DPM in unbound tritiated Hp materials.
Figure 5
Binding Curves of GAGs to HIP Peptide-1. Dilutions of Hp, CS-E, DS, CS-C or Bovine kidney-HS (BK-HS) were added in 
400 µl PBS to 100 µl of a 1:1 slurry of HIP peptide-1 sepharose : PBS. After a 10-minute incubation, the tubes were washed 
with three serial dilutions of 500 µl PBS. Bound materials were eluted with 2 M NaCl and quantified as in "Materials and Meth-
ods." Values shown are the total amounts bound (Y-axis) versus the concentration of the material added (X-axis). Hp, CS-E, 
and DS were fitted to a logarithmic curve with r squared values of 0.81 or greater.Journal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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When the starting material used for fractionation on a HIP
peptide-1 column is Hp byproducts, a charge dependent
increase in ATIII-dependent anti FXa activity for bound
materials is seen. Hp byproducts are a very heterogeneous
mixture of GAGs. Due to the nature of the Hp/HS biosyn-
thetic pathways, the ATIII binding pentasaccharide is
formed preferentially in highly negatively charged regions
[1]. Our hypothesis is that HIP peptide-1 chromatography
does not enrich for anticoagulant activity from Hp by-
products on the basis of a bio-specific interaction with the
ATIII binding pentasaccharide but rather due to non-spe-
cific charge interactions. This hypothesis was substantiat-
ed by comparing the charge characteristics of Hp
byproducts depleted of HIP peptide-1 or ATIII binding ac-
tivity. Also, the binding ability of HIP peptide-1 for Hp
byproducts depleted of ATIII binding activity was deter-
mined. Firstly, elution profiles from anion exchange chro-
matography show that ATIII binding species have an
increased charge profile when compared to starting mate-
rial, but the ATIII-depleted materials are only slightly
shifted to a less negatively charged profile compared to
starting material. In contrast, HIP peptide-1 depleted Hp
byproducts are essentially depleted of its most negatively
charged species. This shows that highly negatively charged
species within Hp byproducts are associated with, but not
sufficient for ATIII interaction while HIP peptide-1 has a
simple charge requirement. Secondly, HIP peptide-1
binds some ATIII depleted Hp byproducts indicating that
the ATIII binding pentasaccharide is not essential for HIP
peptide-1 binding. The inherently high negative charge of
ATIII binding species [11,12] and the charge heterogenei-
ty of Hp byproducts makes the HIP peptide-1 separation
of Hp byproducts into pools with low and high anticoag-
ulant activity possible. In contrast, the relatively homoge-
neously charged Hp preparations tested are refractory to a
similar separation.
Binding studies suggest that HIP peptide-1 has a selectivi-
ty for GAGs of the Hp/HS subclass [13]. This is demon-
strated by the inability of CS-A, DS, CS-C, KS, and HA to
act as effective competitors for HIP peptide-1 binding to
tritiated Hp. Additionally, HIP peptide-1 is found to bind
subsets of cell surface JAR cell HS and DS, suggesting dif-
ferentiation within a class of GAG. Binding potential is in-
creased in pools of JAR cell HS or DS that have longer
length and higher sulfation content. Likewise, Hp byprod-
ucts bound in the presence of 0.20 M have increased size
(D.E.H. and M.H. unpublished observations) and charge
when compared to Hp byproducts bound in 0.15 M NaCl.
The new interpretation of this data is that HIP peptide-1
binds GAGs via a threshold charge and not due to inher-
ent bio-specificity. This is further supported by the deter-
mined hierarchy of binding potential; Hp > CS-E > DS >
CS-C = BK-HS, which mimics the charge density order of
the GAGs; suggesting that the sulfation content is the
most important factor in the interaction with HIP pep-
tide-1 and not the subclass of GAG.
Theoretically, it should be possible to create linear pep-
tides that can specifically bind to 'sequences' within the
linear GAG chain. Our current knowledge on Hp/HS
binding motifs has come from an examination of Hp/HS
binding proteins that identified the XBBXBX and
XBBBXXBX motifs where X is an uncharged or hydropho-
bic amino acid and B is a basic amino acid [14]. It is im-
portant to note that HIP peptide-1
(CRPKAKAKAKAKDQTK) does not exactly correspond to
either of these motifs yet binds Hp/HS. However, studies
have shown that concatamers of peptides that conform to
these consensus motifs have binding affinity proportional
to the number of subunits [15] and can reverse the anti-
thrombotic activity of Hp in vivo [16]. A natural example
of a concatamer of Hp/HS binding motifs is human HIP/
RPL29. This protein is highly basic with 29.5% of Lys/Arg
content distributed evenly throughout the protein. Stud-
ies with deletion mutants of human HIP/RPL29 show that
Hp/HS binding ability increases with the length of dele-
tion mutant, irrespective of domain [17]. Concatamers of
Hp/HS binding sequences may be a common mechanism
of protein/GAG interactions. Future work will be aimed at
identifying novel proteins and peptide sequences that spe-
cifically interact with ATIII binding Hp/HS.
Materials and Methods
Materials
Porcine intestinal mucosa heparin (product number
H3393), bovine kidney heparan sulfate, dermatan sulfate,
and chondroitin sulfate C, were purchased from Sigma.
Chondroitin Sulfate E was purchased from CalBiochem.
Tritiated heparin (0.44 mCi/mg) was purchased from
NEN life science products. DEAE resin was purchased
from Pharmacia. Heparin byproducts were obtained from
Scientific Protein Laboratories (division of Viobin corpo-
ration) Waunakee, WI. Human blood plasma was ob-
tained from the Houston Blood Center (Houston, TX).
HIP peptide-1 affinity chromatography
HIP peptide-1 affinity resin was prepared as in Liu et al.,
[7]. One mg Hp or 40 ng tritiated Hp was applied to HIP
peptide-1 affinity resin in 0.15 M NaCl, phosphate buffer,
allowed to bind for 10 min and washed with 10 column
volumes of 0.15 M NaCl phosphate buffer. Then 0.5 M
NaCl was used to elute any bound Hp or tritiated Hp. A
final elution with 3 M NaCl was employed for tritiated
Hp. Hp byproducts were applied to 3 mls of a HIP pep-
tide-1 affinity matrix in PBS, washed with 15 mls PBS, and
eluted w/ a 0.15 M to 0.70 M NaCl gradient. Material for
the bulk separation of Hp byproducts were initially added
in 0.25 M NaCl, under subsaturating conditions, washed
with ten column volumes of 0.25 M NaCl and finallyJournal of Negative Results in BioMedicine 2003, 2 http://www.jnrbm.com/content/2/1/1
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eluted with 1 M NaCl. Subsequent experiments for the
bulk separation of Hp byproducts took the flow through
from the previous salt separation and diluted them to 0.2
M, and then 0.15 M for the serial separation of materials
with decreasing stringency. Five different column runs
were done at each step to create HIP 0.20 M, HIP 0.15 M
and HIP flow through pools. One ml fractions were col-
lected and salt concentrations were determined against a
standard curve using a conductivity meter.
GAG quantitation
A Blyscan (Biocolor, Ltd.; Belfast, Ireland) assay was used
for the quantitation of GAGs in experiments using unla-
belled GAGs. The assay is based on the specific binding of
the cationic dye; 1,9-dimethyl methylene blue to sulphat-
ed GAGs [18]. A standard curve of the relevant material
was made during each quantitation that had a correlation
coefficient of 0.96 or greater. Unknown solutions were di-
luted to <0.5 M NaCl where applicable and quantitation
performed in at least duplicate. Quantitation of tritiated
Hp was performed by liquid scintillation counting.
Anion exchange chromatography for the determination of 
GAG charge
A 1 ml DEAE column was pre-equilibrated in 0.05 M Ace-
tate pH 4.0 and GAGs applied [19]. Columns were
washed in acetate buffer for 10 column volumes before
the start of LiCl gradients ranging from 0 to 2 M LiCl. In
some experiments where it was previously determined
that 100% of the GAGs bound to the column, washing
steps were omitted and LiCl gradients started at fraction
one. One-ml fractions were collected and quantified in
the Blyscan assay against a standard curve or radioactivity
counted by liquid scintillation counting. A standard curve
for LiCl was also made and read on a conductivity meter
enabling the conversion of experimental conductivity
readings to LiCl concentration. Data from these experi-
ments were analyzed by assigning the maximum peak of
elution an arbitrary value of 100. All other values were
multiplied by the same factor and elution profiles from
LiCl concentration (X-axis) versus arbitrary (Y-axis) were
made. A line running through the transformed elution
profiles 50 arbitrary value was made and the two intersec-
tion points of LiCl concentration were noted. These two
intersection values were averaged to determine the LiCl
concentration for elution peaks. The LiCl concentration
for elution peak in experiments where multiple elution
profiles were made, was an average of the individual
averages.
FXa activity of GAG fractions
Clinical kits (Sigma, St. Louis, MO) were used in the de-
termination of ATIII – dependent Hp activity in FXa inhi-
bition as described in the corresponding instructions
except that Hp / Hp byproducts materials were added in
place of plasma. Briefly, this kit uses ATIII, FXa, and a
chromogenic substrate for FXa to measure Hp concentra-
tions in blood. This assay has been utilized to measure the
relative activity of fractionated Hp byproducts to acceler-
ate the inactivation of FXa by ATIII-Hp complexes as
measured by comparisons in ATIII-GAG – dependent in-
hibition of substrate cleavage measured at 405 nm. Gly-
cosaminoglycan containing solutions were diluted to 0.15
M NaCl before use in the assay. Enrichment or depletion
of FXa activity was determined by identifying the concen-
tration of Hp byproducts at which FXa activity was inhib-
ited 1/2 maximally (1/2 maxinh). The 1/2 maxinh
concentration of the starting material was divided by the
1/2 maxinh concentration of the sample to determine fold
increase in FXa activity over starting material.
Antithrombin III affinity chromatography
Antithrombin III was purified from human plasma as de-
scribed in Wickerhauser and Williams [20]. The purified
ATIII was then linked to CNBr activated Sepahrose in the
presence of excess N-acetylated Hp as in Höök et al., [2].
Hp byproducts were applied to the ATIII column in PBS,
washed with 10 column volumes and bound material
eluted in phosphate buffer containing 3 M NaCl. Flow
through materials was subjected to ATIII chromatography
5 times. After the third time, no bound material was de-
tected. Thus, th5 times ATIII flow through is completely
depleted of ATIII binding sites. This was confirmed by a
lack of activity in the FXa assay (data not shown).
GAG binding assays
Multiple tubes containing 100 µl of a 1:1 suspension of
HIP peptide-1 Sepharose in PBS were assembled. Four
hundred µl of UF Hp (Sigma), bovine kidney heparan sul-
fate (Sigma), chondroitin sulfate-C (Sigma), dermatan
sulfate (Sigma), or chondroitin sulfate-E (CalBiochem),
was added in a range of concentrations from 50 µg/ml to
1500 µg/ml. The mixtures were incubated at room tem-
perature for thirty minutes after an initial vortexing. The
tubes were then centrifuged at 16,000 × G for 5 min and
the liquid aspirated, leaving resin in the tube. Then, 500
µl of PBS was added to the resin bed, vortexed, centri-
fuged, and liquid aspirated. This cycle was done three
times to ensure a 1:1000 final dilution of initially added
GAGs. After a final aspiration, 50 µl of 2 M NaCl in phos-
phate buffer was added, releasing any bound material into
the liquid phase. Aliquots of this material were quantified
by the Blyscan assay and µg/ml GAG added (X-axis) versus
total µg GAG bound (Y-axis) plots were made.
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